Signs of angels come at the most unexpected — yet vital — moments in our lives, columnist Juliet Taylor writes.

The analyses offer evidence for a slowing of functional decline and improved survival outcomes with long-term Radicava ORS by ...

Taking short breaks from caregiving to enjoy time with her community in nature is a way to feed the soul, says columnist.

Neither memantine nor trazodone was able to slow amyotrophic lateral sclerosis (ALS) disease progression in a platform ...

A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

ALS symptom progression brings challenges, but for columnist Dagmar Munn, the key to living well with the disease is to be ...

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...

A Texas Children’s Hospital investigator won a $2.4 million NIH grant for ALS and other neurodegenerative disease research.

The Scott-Morgan Foundation is launching a joint initiative that aims to use AI technologies to help improve communication ...

After her late husband's diagnosis anniversary, columnist Juliet Taylor reflects on how grief became a heavy burden and a ...

NeuroSense plans to apply to Canada’s regulators for early marketing approval of the oral therapy, supported by a Phase 2b ...